Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection

Bibliography

• Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014;20:9633-52
   PubMed Web of Science ®Google Scholar
• Penin F, Dubuisson J. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19
   PubMed Web of Science ®Google Scholar
• Gower E, Estes CC, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45-57
   PubMed Web of Science ®Google Scholar
• Reddy KR, Bruno S, Rossaro L, et al. Predictors of sustained virologic response among treatment-naïve patients with hepatitis C virus genotype 1 when treated with boceprevir (boc) plus peginterferon alfa-2b/ribavirin (pr). J Hepatol 2011;54:S190
   Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16
   PubMed Web of Science ®Google Scholar
• Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: ameta-analysis. J Hepatol 2009;50:1142-54
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-40
   PubMed Web of Science ®Google Scholar
• Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39:478-87
   PubMed Web of Science ®Google Scholar
• Lormeau C, Falgarone G, Roulot D, et al. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006;73:633-8
   PubMed Web of Science ®Google Scholar
• Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 2006;8:53-9
   PubMedGoogle Scholar
• Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev 2008;8(1):1-4
   PubMed Web of Science ®Google Scholar
• Landau DA, Saadoun D, Calabrese LH, et al. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007;6:581-7
   PubMed Web of Science ®Google Scholar
• Monti G, Saccardo F, Castelnovo L, et al. Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmun Rev 2014;13:609-14
   PubMed Web of Science ®Google Scholar
• Burrows NP, Norris PG, Alexander G, et al. Chronic hepatitis C infection and psoriasis. Dermatology 1995;190:173
   PubMed Web of Science ®Google Scholar
• Chouela E, Abeldano A, Panetta J, et al. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996;35:797-9
   PubMed Web of Science ®Google Scholar
• Taglione E, Vatteroni ML, Martini P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999;26:370-2
   PubMed Web of Science ®Google Scholar
• Palazzi C, D’Angelo S, Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev 2008;8:48-51
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78
   PubMedGoogle Scholar
• Soscia E, Sirignano C, Catalano O, et al. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 2012;89:49-53
   PubMedGoogle Scholar
• Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) 2011;63:1091-7
   PubMed Web of Science ®Google Scholar
• Tillett W, Costa L, Jadon D, et al. The classification for psoriatic arthritis (CASPAR) criteria–a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39:154-6
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 2012;39:849-55
   PubMed Web of Science ®Google Scholar
• Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl 2012;89:4-6
   PubMedGoogle Scholar
• Del Puente A, Esposito A, Parisi A, et al. Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 2012;89:36-8
   PubMedGoogle Scholar
• Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012;31:711-15
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010;8:331-4
   PubMed Web of Science ®Google Scholar
• Shang Q, Tam LS, Sanderson JE, et al. Increase in ventricular–arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 2012;51:2215-23
   PubMed Web of Science ®Google Scholar
• Scarpa R, Manguso F, D’Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6
   PubMed Web of Science ®Google Scholar
• Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 2013;72:1956-61
   PubMed Web of Science ®Google Scholar
• Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015;54(1):20-8
   PubMed Web of Science ®Google Scholar
• Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012;64:107-12
   PubMedGoogle Scholar
• Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-6
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Bellisai F, Giannitti C, et al. Safety of cyclosporine in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007;1110:544-9
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8:100-3
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Bellisai F, Manganelli S, et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006;5:493-8
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-41
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014;58:61-9
   PubMed Web of Science ®Google Scholar
• Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2:346-57
   PubMed Web of Science ®Google Scholar
• Scarpa R, Costa L, Atteno M, et al. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 2013;14:2311-13
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013;80:165-70
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014;33:833-9.63
   PubMed Web of Science ®Google Scholar
• Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011;30:1063-7
   PubMed Web of Science ®Google Scholar
• Atteno M, Costa L, Matarese A, et al. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014;33:543-7
   PubMed Web of Science ®Google Scholar
• Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014;2014:862969
   PubMed Web of Science ®Google Scholar
• Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26
   PubMed Web of Science ®Google Scholar
• Fuchs I, Abu-Shakra M, Sikuler E. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations. Isr Med Assoc J 2013;15:303-7
   PubMed Web of Science ®Google Scholar
• Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012;12:193-207
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
   PubMed Web of Science ®Google Scholar
• Park J, Kang W, Ryu SW, et al. Hepatitis C virus infection enhances TNFα-induced cell death via suppression of NF-κB. Hepatology 2012;56:831-40
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-74
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Marinos G, Ffrench RA, et al. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-36
   PubMed Web of Science ®Google Scholar
• Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23:210-17
   PubMed Web of Science ®Google Scholar
• Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Adv Exp Med Biol 2013;783:121-40
   PubMed Web of Science ®Google Scholar
• Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010;6:165-74
   PubMed Web of Science ®Google Scholar
• Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003;14:229-32
   PubMedGoogle Scholar
• Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580-4
   PubMed Web of Science ®Google Scholar
• Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361-2
   PubMed Web of Science ®Google Scholar
• De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006;54:1102-4
   PubMed Web of Science ®Google Scholar
• Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007;32:18-22
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26:261-4
   PubMed Web of Science ®Google Scholar
• Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34:1353-5
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Ceribelli A, Cattaneo R, et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8:104-6
   PubMed Web of Science ®Google Scholar
• Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008;27:346-7
   PubMed Web of Science ®Google Scholar
• Paradisi A, Caldarola G, Capizzi R, et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010;62:1067-9
   PubMed Web of Science ®Google Scholar
• Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol 2010;23:965-9
   PubMed Web of Science ®Google Scholar
• Cuchacovich R, Hagan J, Khan T, et al. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol 2011;30:133-7
   PubMed Web of Science ®Google Scholar
• Zanni M, Missale G, Santilli D, et al. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011;21:564-7
   PubMed Web of Science ®Google Scholar
• Mederacke I, Witte T, Wedemeyer H, et al. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis 2011;70:1343-4
   PubMed Web of Science ®Google Scholar
• Abuchar A, Vitiello M, Kerdel FA. Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol 2013;52:381-2
   PubMed Web of Science ®Google Scholar
• Colombo D, Chimenti S, Grossi P, et al. Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis–synergy study: a longitudinal observational study. Biomed Res Int 2014;2014:941767
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014;33:273-6
   PubMed Web of Science ®Google Scholar
• Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22
   PubMed Web of Science ®Google Scholar
• Cooper C, Shafran S, Greenbloom S, et al. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. Can J Gastroenterol Hepatol 2014;28:35-40
   Google Scholar
• Afshar M, Martinez AD, Gallo RL, et al. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013;27:771-8
   PubMed Web of Science ®Google Scholar